A Trial of Observed Long-acting, Anti-HIV Treatment With a Monoclonal CCR5 Antibody (PRO 140) as an Adjunct to a New, Optimized, Oral Antiretroviral Regimen in HIV-infected Injection Drug Users With Viral Rebound and Documented Poor Adherence

This study is currently recruiting participants. (see Contacts and Locations)

Verified November 2015 by CytoDyn, Inc.

Sponsor:

Information provided by (Responsible Party):

CytoDyn, Inc.

ClinicalTrials.gov Identifier:

NCT01272258

First received: January 5, 2011

Last updated: November 17, 2015

Last verified: November 2015

No Study Results Posted on ClinicalTrials.gov for this Study

Study Status:	This study is currently recruiting participants.
Estimated Study Completion Date:	February 2017
Estimated Primary Completion Date:	January 2017 (Final data collection date for primary outcome measure)